When was EvolutionaryScale founded?

EvolutionaryScale was founded in 2023 and raised its 1st funding round 1 year after it was founded.

Where is EvolutionaryScale located?

EvolutionaryScale is headquartered in New York City, United States. It is registered at ANGLO DAL HOUSE,5 SPRING VILLA PARK,EDGWARE,MIDDLESEX,UNITED KINGDOM,HA8 7EB.

Who is the current CEO of EvolutionaryScale?

Alexander Rives of EvolutionaryScale. They have also founded 1 company.

Is EvolutionaryScale a funded company?

EvolutionaryScale is a funded company, having raised a total of $***** in its 1st and only funding round, a Seed round on Jun 25, 2024.

When was the latest funding round of EvolutionaryScale?

EvolutionaryScale's latest funding was a $***** Seed round on Jun 25, 2024, with participation from 5 investors. Its primary sector is Life Sciences Tech. In United States, the Life Sciences Tech sector has seen $2.13B in funding in 2026 to date.

Where does EvolutionaryScale rank among its competitors?

EvolutionaryScale ranks 4th amongst 79 active competitors, of which 42 are funded. It stands 8th in terms of total funding among its competitors. The most recent competitor to raise funding was Profluent Bio, which secured $106M in Nov, 2025.

Who are the top competitors of EvolutionaryScale?

EvolutionaryScale's top competitors include Nimbus Therapeutics, Generate Biomedicines and Cradle. Among them, Profluent Bio secured the most recent funding round in November, 2025.

EvolutionaryScale - 2026 Company Profile, Team, Funding & Competitors

Company Details

Provider of an AI models for protein design. The company has developed ESM3, a frontier language model for biology that can simultaneously reason over the sequence, structure, and function of proteins.

Website: www.evolutionaryscale.ai/
Social
Email ID: *****@evolutionaryscale.ai
Registered Address: ANGLO DAL HOUSE,5 SPRING VILLA PARK,EDGWARE,MIDDLESEX,UNITED KINGDOM,HA8 7EB

Key Metrics

Founded Year

2023

Location

New York City, United States

Stage

Seed

Total Funding

$142M in 1 round

Latest Funding Round

Seed, Jun 25, 2024, $*****

Investors

Lux Capital & 4 more

Ranked

4^th among 79 active competitors

Similar Companies

OpenEvidence & 2418 more

View EvolutionaryScale's full profile

EvolutionaryScale is associated with 1 legal entity given below:

Legal Entity Name	Date of Incorporation	Revenue	Latest Employee Count	Documents
SINAPSIS LTD CIN: 7530283 , United Kingdom, Active	Feb 14, 2011	-	1 (As on Mar 31, 2025)

EvolutionaryScale has raised a total funding of $142M over 1 round. Its latest funding round was a Seed round on Jun 25, 2024 for $*****. 5 investors participated in its latest round. EvolutionaryScale has 3 institutional investors and 2 angel investors.

Here is the list of recent funding rounds of EvolutionaryScale:

Date of Funding	Funding Amount	Round Name	Post-Money Valuation	Revenue Multiple	Lead Investors	Other Investors
Jun 25, 2024	4949368	Seed	7242965	3238120	1533924	2173407

Access funding benchmarks and valuations. Sign up today!

View details of EvolutionaryScale's funding rounds and investors

The founders of EvolutionaryScale are Alexander Rives, Tom Sercu, Thomas Hayes, Roshan Rao and Halil Akin. Alexander Rives is the CEO of EvolutionaryScale.

Here are the details of EvolutionaryScale's key team members:

Alexander Rives: Co-Founder & CEO of EvolutionaryScale.
Contact Info: 1 email address
Tom Sercu: Co-founder, VP of Engineering of EvolutionaryScale.
Thomas Hayes: Co-Founder of EvolutionaryScale.
Roshan Rao: Co-Founder of EvolutionaryScale.
Contact Info: 1 email address
Halil Akin: Co-Founder of EvolutionaryScale.
Contact Info: 1 email address

View details of EvolutionaryScale's Founder profiles and Board Members

Access Tracxn on any website

Our Google Chrome extension lets you view company details while browsing their websites

Install Tracxn Extension

Top competitors of EvolutionaryScale include Nimbus Therapeutics, Generate Biomedicines and Cradle. Here is the list of Top 10 competitors of EvolutionaryScale, ranked by Tracxn score:

Rank	Company Details	Short Description	Total Funding	Investors	Tracxn Score
1st	Nimbus Therapeutics 2009, Cambridge (United States), Series F	Developer of targeted therapeutics for cancer, metabolic and inflammatory diseases	$637M	BVF Partners, Atlas Venture & 20 others	68/100
2nd	Generate Biomedicines 2018, Somerville (United States), Public	Developer of a platform for generating novel protein-based therapeutic modalities	$693M	NVentures, March Capital & 14 others	66/100
3rd	Cradle 2021, Zurich (Switzerland), Series B	Provider of chemoproteomics solutions for protein design and development	$103M	Index Ventures, IVP & 7 others	64/100
4th	EvolutionaryScale 2023, New York City (United States), Seed	Provider of an AI models for protein design	$142M	Amazon, NVentures & 3 others	64/100
5th	Profluent Bio 2022, Berkeley (United States), Series B	Provider of an artificial intelligence-based protein design platform	$150M	Insight Partners, Altimeter Capital & 6 others	64/100
6th	Frontier Medicines 2018, San Francisco (United States), Series C	Developer of a bioinformatics platform for drug development and chemoproteomics	$236M	Deerfield, RA Capital Management & 11 others	64/100
7th	Eikon 2019, Millbrae (United States), Public	Protein tracking and measuring tool for drug discovery	$1.16B	The Column Group, Foresite Capital & 22 others	62/100
8th	Seismic 2019, Watertown (United States), Series B	AI-assisted platform for drug discovery and development	$247M	Lightspeed Venture Partners, Bessemer Venture Partners ... & 12 others	61/100
9th	Vividion Therapeutics 2016, Oceanside (United States), Acquired	Pioneering chemoproteomics and covalent chemistry for precision therapeutics targeting undruggable disease drivers	$271M	Boxer Capital, Versant Ventures & 21 others	61/100
10th	Orbit Discovery 2015, Oxford (United Kingdom), Series A	Developer of a drug discovery platforms by peptide display engine	$15.7M	Oxford Science Enterprises, Innovate UK & 11 others	59/100